About this trial
The goal of this clinical trial is to have a successful engraftment in after bone transplantation. Acute leukemia patient of both sexes aged 2 to 18 years, who are transplant candidates, participate in this study. Primary hypothesis is Patients receiving SMOF LIPID will have better grafts than patients receiving intralipid. Also, complications after surgery and malnutrition will be less in this group.
Eligibility criteria
Qualifiers
Willingness to cooperate and complete the informed consent form by the legal guardian of the child;
Age ≤ 18 years;
Definitive diagnosis of acute leukemia and candidate for hematopoietic stem ● cell transplantation;
Eligible for parenteral nutrition support;
Disqualifiers
Death of the child earlier than 5 days from the start of the intervention;
Unwillingness to continue cooperation during study;
Occurrence of side effects during the study;
In case of sepsis, hypotension, shock, thrombosis, myocardial infarction, liver dysfunction, the patient will be excluded from the study.
Trial design
Treatments tested in this trial
- SMOF lipid
- INTRALIPIDS